We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-13%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$515M
AUM Growth
-$122M
Cap. Flow
+$31.4M
Cap. Flow %
6.1%
Top 10 Hldgs %
68.79%
Holding
51
New
3
Increased
5
Reduced
9
Closed
–

Top Buys

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$17.3M
2
IOBT
IO Biotech
IOBT
+$10.8M
3
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$9.99M
4
LENZ
LENZ Therapeutics
LENZ
+$4.97M
5
VTVT icon
vTv Therapeutics
VTVT
+$2.2M

Top Sells

Rank Stock Value
1
RXRX icon
Recursion Pharmaceuticals
RXRX
+$4.02M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$3.28M
3
TIL icon
Instil Bio
TIL
+$2.96M
4
SWTX
SpringWorks Therapeutics
SWTX
+$1.96M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$1.05M

Sector Composition

Rank Sector Weight
1 Healthcare 95.86%
2 Financials 1.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LENZ
1
LENZ Therapeutics
LENZ
$172M
$97.6M 18.93%
1,121,705
+60,045
+6% +$4.97M
KDNY
2
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$74.9M 14.53%
4,591,888
+1,215,000
+36% +$17.3M
TIL icon
3
Instil Bio
TIL
$48.4M
$34.1M 6.61%
99,598
-7,672
-7% -$2.96M
NKTX icon
4
Nkarta
NKTX
$162M
$31.2M 6.06%
2,034,703
– –
STRO icon
5
Sutro Biopharma
STRO
$379M
$24.9M 4.84%
167,558
– –
FMTX
6
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$22.3M 4.32%
1,565,526
– –
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$21.1M 4.1%
1,262,551
-200,283
-14% -$3.28M
RAIN
8
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$20.2M 3.93%
1,571,379
– –
CNTA
9
DELISTED
Centessa Pharmaceuticals
CNTA
$16.4M 3.19%
1,459,693
-77,840
-5% -$1.05M
NVAX icon
10
CALL
Novavax
NVAX
$1.23B
$11.8M 2.29%
82,600
– –
ACRS icon
11
Aclaris Therapeutics
ACRS
$730M
$11.5M 2.24%
794,171
– –
SNCE
12
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$11.2M 2.18%
+45,000
New +$9.99M
ICPT
13
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$10.4M 2.02%
640,688
– –
RXRX icon
14
Recursion Pharmaceuticals
RXRX
$1.57B
$9.24M 1.79%
539,236
-213,703
-28% -$4.02M
SWTX
15
DELISTED
SpringWorks Therapeutics
SWTX
$8.69M 1.69%
140,267
-29,585
-17% -$1.96M
JANX icon
16
Janux Therapeutics
JANX
$935M
$8.13M 1.58%
411,871
– –
VRNA
17
DELISTED
Verona Pharma
VRNA
$7.47M 1.45%
1,111,112
– –
IOBT
18
DELISTED
IO Biotech
IOBT
$7.17M 1.39%
+1,120,437
New +$10.8M
TNGX icon
19
Tango Therapeutics
TNGX
$4.34B
$6.89M 1.34%
630,000
-70,000
-10% -$842K
SYRS
20
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.24M 1.21%
218,920
– –
EYPT icon
21
EyePoint Inc
EYPT
$1.02B
$5.88M 1.14%
480,000
+30,000
+7% +$404K
ELEV
22
DELISTED
Elevation Oncology
ELEV
$5.61M 1.09%
932,240
– –
AVDL
23
DELISTED
Avadel Pharmaceuticals
AVDL
$5.33M 1.03%
659,409
+110,159
+20% +$1.01M
JYAC
24
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.95M 0.96%
507,041
– –
SYRE icon
25
Spyre Therapeutics
SYRE
$8.87B
$4.2M 0.81%
35,349
– –
1
2 3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q4 2021 Portfolio in Review

As of Q4 2021, Samsara BioCapital held 51 positions worth $515M, down 19% from $637M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Samsara BioCapital deployed $31.4M of net new capital in Q4 2021, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was IO Biotech: 1,120,437 shares worth $7.17M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Recursion Pharmaceuticals, an estimated $4.02M trimmed.

  • Samsara BioCapital's largest Q4 2021 buy was IO Biotech: 1,120,437 shares worth $7.17M.
  • Samsara BioCapital added most to Chinook Therapeutics, Inc. Common Stock in Q4 2021, an estimated $17.3M increase.
  • Samsara BioCapital's biggest Q4 2021 reduction was Recursion Pharmaceuticals, cutting an estimated $4.02M.
  • Samsara BioCapital's ten largest holdings make up 69% of its $515M portfolio in Q4 2021.
  • Samsara BioCapital opened 3 new positions and closed 0 in Q4 2021.
  • Samsara BioCapital's portfolio value fell 19% quarter-over-quarter to $515M.

Based on Samsara BioCapital's 13F filing for Q4 2021, filed 14 Feb 2022.